Lee's Pharmaceutical Holdings Ltd (HKSE:00950) Share Price

Company Profile

Business description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People’s Republic of China.
Contact
Hong Kong Science Park
1st Floor, Building 20E, Phase 3
Shatin
Hong Kong
HKG
T: +852 23141282
https://www.leespharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2025
Employees
1,022

Recommended

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.

Malik Ahmed Khan, CFA | 05 September 2025

A difficult year but better times ahead.

Johannes Faul, CFA | 05 September 2025

Find out how this defensive player has fared after earnings.

Simonelle Mody | 03 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,140.50	11.00	0.12%
CAC 40	7,674.78	24.14	-0.31%
DAX 40	23,596.98	173.35	-0.73%
Dow JONES (US)	45,400.86	220.43	-0.48%
FTSE 100	9,208.21	8.66	-0.09%
HKSE	25,417.98	359.47	1.43%
NASDAQ	21,700.39	7.30	-0.03%
Nikkei 225	43,018.75	438.48	1.03%
NZX 50 Index	13,223.53	90.33	0.69%
S&P 500	6,481.50	20.58	-0.32%
S&P/ASX 200	8,871.20	8.60	0.10%
SSE Composite Index	3,812.51	46.64	1.24%